

ASX Announcement

23 Mar 2022

emyria

myriad data.
individual care.

Emyria to present webinar, March 24th

Emyria Limited (ASX: EMD) (Emyria or the Company), a clinical stage biotechnology company leveraging real-world patient data to develop treatments for unmet needs, is pleased to announce its participation in the free **Broker Briefing 'Technology / Biotechnology Investor Webinar'**, to be held **Thursday 24th of March 2022 from 11:30am AEDT / 8:30am AWDT**.

Managing Director, Dr. Michael Winlo will provide an overview of the Company's advances in clinical drug development and care delivery, including its recently launched proprietary, ultra-pure CBD formulation, EMD-RX7, and its expanded proprietary MDMA analogue library, to be used for psychedelic assisted therapies and other neuropsychiatric disorders.

This webinar is able to be viewed live via Zoom and will provide viewers the opportunity to hear from, and engage with, a range of tech/biotech ASX-listed leading micro/mid cap companies.

A recorded copy of the webinar will be made available following the event.

A copy of the investor presentation to be delivered during the webinar will be released on the day of the event.

Details of the event are as follows:

- **Event:** Broker Briefing Tech / Biotech Investor Webinar
- **Webinar Presenter:** Emyria's Managing Director, Dr. Michael Winlo
- **Date and Time:** Thursday 24th March, 11:30am Sydney time (AEDT)
- **Speaking Time:** 11:40am AEDT / 8:40am AWST

To register, please click on the link below:

https://zoom.us/webinar/register/9816461303078/WN_gezMXs5iSBe4LEINQm-laA

This announcement has been approved and authorised for release by the Managing Director of Emyria Limited

For further information:

Dr. Michael Winlo
Managing Director
+61 (0) 8 6559 2800
mwinlo@emyria.com

Lexi O'Halloran
Media/Investor Relations
+ 61 (0) 404 577 076
investors@emyria.com

Andrew Williams
Media Relations
+61 (0) 412 614 125
awilliams@emyria.com



About Emyria (www.emyria.com)

Emyria Limited develops biopharmaceuticals guided by proprietary Real-World Data collected with patients across its wholly-owned clinical service subsidiary, Emerald Clinics.

Emyria's current clinical development programs are focussed on the registration of proprietary formulations of cannabinoid-based medical treatments (CBMTs) and novel MDMA ('ecstasy') analogues with major global regulators. Emyria's programs target major unmet needs such as mental health disorders and chronic pain.

Emyria's Real World Data (RWD) guides each of Emyria's clinical development programs and care models. Emyria RWD is deep, ethically-sourced clinical evidence gathered with thousands of patients who also receive personalised care at Emerald Clinics.

Emyria is therefore uniquely providing care to patients, generating clinical evidence and advancing multiple proprietary treatment programs towards registration.

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.